MicroRNAs in mutagenesis, genomic instability, and DNA repair.

abstract：:Organ function preservation in patients with head and neck cancer can be achieved by intensity-modulated radiation therapy (IMRT). Much of the work on the physics of IMRT has been done for currently available IMRT systems. However, clinical data remain scarce. Before IMRT is accepted as a standard of care, more compre...

journal_title：Seminars in oncology

authors： Chao KS,Ozyigit G,Thorsdad WL

更新日期：2003-12-01 00:00:00

abstract：:Monoclonal antibodies directed at the lymphoid antigens have become established treatments for hematological malignancies either alone or in combination with chemotherapy. However, their incorporation in the transplant setting remains investigational. This review focuses on the currently available data for in vitro an...

journal_title：Seminars in oncology

authors： Wasil T,Rai KR,Mehrotra B

更新日期：2004-02-01 00:00:00

abstract：:We review the options for the treatment of newly diagnosed myeloma in a patient who is a candidate for autologous stem cell transplantation (ASCT). Bortezomib, lenalidomide, dexamethasone (VRD) has been studied in two randomized trials as first-line therapy. In one of these trials, VRD demonstrated improved overall su...

journal_title：Seminars in oncology

authors： Rajan AM,Rajkumar SV

更新日期：2016-12-01 00:00:00

abstract：:As antineoplastic therapy improves, patients with cancer will have the potential for prolonged survival. Tumor products may produce metabolic complications, such as hypercalcemia, hyponatremia, and hypoglycemia, and these conditions must be promptly recognized so that treatment can be initiated before severe or life-t...

journal_title：Seminars in oncology

authors： Silverman P,Distelhorst CW

更新日期：1989-12-01 00:00:00

abstract：:In 2002, the American Joint Committee on Cancer (AJCC) revised the staging system for cutaneous melanoma on the basis of a survival analysis of important melanoma prognostic factors. Features of the revised system include new strata for primary tumor thickness, incorporation of primary tumor ulceration as an important...

journal_title：Seminars in oncology

authors： Rousseau DL Jr,Gershenwald JE

更新日期：2004-06-01 00:00:00

abstract：:Over the last 40 years the National Cancer Institute (NCI) has created a vibrant public-private partnership for the implementation of NCI-sponsored cooperative group (Network) clinical trials throughout the United States and Canada. Over these four decades, the cancer clinical trials process has become more complex mo...

journal_title：Seminars in oncology

authors： Lloyd Wade J 3rd,Petrelli NJ,McCaskill-Stevens W

更新日期：2015-10-01 00:00:00

abstract：:Small cell carcinoma (SCC) has become recognized as a distinct, though relatively infrequent, clinical pathology that occurs in multiple sites throughout the head and neck. Excluding cases that are considered to arise from skin, SCC in the head and neck has been found to develop in nearly all structures associated wit...

journal_title：Seminars in oncology

authors： Renner G

更新日期：2007-02-01 00:00:00

abstract：:Clinical research in the treatment of epithelial ovarian cancer has entered a new phase. A pivotal Gynecologic Oncology Group study demonstrated that paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) plus cisplatin was superior to the previous standard therapy of cyclophosphamide plus cisplatin. Confirma...

journal_title：Seminars in oncology

authors： Ozols RF

更新日期：1997-10-01 00:00:00

abstract：:Adrenocortical cancer (ACC) is a rare, challenging disease with a broad range of clinical presentations. Often presenting in an advanced stage with a large, locally invasive primary tumor or with Cushing's syndrome, it requires a multidisciplinary approach to treatment. We discuss controversies in the evaluation and m...

journal_title：Seminars in oncology

authors： Balasubramaniam S,Fojo T

更新日期：2010-12-01 00:00:00

abstract：:Transport of folates and antifolates in most cells is mediated by the reduced folate carrier (RFCI), an anion exchanging concentrative process, which is opposed by independent exit pump(s) that are directly coupled to energy metabolism. The balance of these processes governs the free intracellular folate level that is...

journal_title：Seminars in oncology

authors： Sierra EE,Goldman ID

更新日期：1999-04-01 00:00:00

abstract：:The role of radiation therapy in the management of breast cancer continues to evolve. For patients with early stage breast cancer, hypofractionated whole breast irradiation following breast conserving surgery now represents the standard of care based on randomized data with long-term efficacy and toxicity outcomes. Pa...

journal_title：Seminars in oncology

authors： Shah C,Bauer-Nilsen K,McNulty RH,Vicini F

更新日期：2020-08-01 00:00:00

abstract：:Since its approval in 2011 for patients with recurrent glioblastoma (GBM), physicians have responded positively to the non-invasive nature of the NovoTTF-100A System device (NovoCure Ltd, Haifa, Israel), citing significantly less toxicity and a better quality of life profile compared to available conventional therapie...

journal_title：Seminars in oncology

authors： Butowski N,Wong ET,Mehta MP,Wilson LK

更新日期：2013-12-01 00:00:00

abstract：:Thus far the development of adjuvant therapies in melanoma has suffered greatly from the lack of effective drugs in stage IV melanoma. Chemotherapy, cytokines, vaccines, and combinations of drugs have been used with minimal success. This has led to adjuvant therapies that are not used uniformly or widely because of th...

journal_title：Seminars in oncology

authors： Eggermont AM,Testori A,Maio M,Robert C

更新日期：2010-10-01 00:00:00

abstract：:Modulation of the signaling pathways that are aberrant in cancer cells has the potential to provide an effective nontoxic approach to patient management in a broad range of cancers. This quest has taken a major leap forward with the demonstration that STI-571 (imatinib mesylate) induces clinical and molecular remissio...

journal_title：Seminars in oncology

authors： Mills GB,Kohn E,Lu Y,Eder A,Fang X,Wang H,Bast RC,Gray J,Jaffe R,Hortobagyi G

更新日期：2003-10-01 00:00:00

abstract：:Lung cancer represents the leading cause of cancer mortality worldwide. Its incidence has declined in men but is increasing in women, assuring that this largely preventable disease will continue to affect millions. In small cell lung cancer, the advent of chemotherapy in the 1970s and continued refinements in the 1980...

journal_title：Seminars in oncology

authors： Splinter TA

更新日期：1997-08-01 00:00:00

abstract：:Coelomic epithelial carcinoma of the ovary, the most common cause of death from cancer of the female genital tract in the United States, presents most commonly as advanced (stage III or IV) disease. Management consists of aggressive surgical cytoreduction followed by combination chemotherapy, until recently, a platinu...

journal_title：Seminars in oncology

authors： Thigpen T,Vance RB,McGuire WP,Hoskins WJ,Brady M

更新日期：1995-12-01 00:00:00

abstract：:Early detection of response to neoadjuvant chemoradiation in esophageal cancer may allow individualization of treatment strategies and avoidance of unnecessary treatment. Although positron emission tomography (PET) with [(18)F]fluorodeoxyglucose (FDG) permits detection of changes in tumor proliferation before any chan...

journal_title：Seminars in oncology

authors： Chao KS

更新日期：2007-04-01 00:00:00

abstract：:The ability to predict the biological behavior of breast tumors can allow selection of the optimum treatment and follow-up strategies. Conventionally, tumor size, lymph node metastases, and histopathologic features have been used to determine the risk of systemic relapse. The discovery of a number of specific genetic ...

journal_title：Seminars in oncology

authors： Dhingra K,Hortobagyi GN

更新日期：1996-08-01 00:00:00

abstract：:Recent studies have indicated that bone marrow angiogenesis is increased in multiple myeloma, suggesting that treatment with an antiangiogenic agent might be useful. Among the new antiangiogenic drugs in development, Neovastat (AE-941; Aeterna Laboratories, Quebec City, Canada) can be classified as a naturally occurri...

journal_title：Seminars in oncology

authors： Falardeau P,Champagne P,Poyet P,Hariton C,Dupont E

更新日期：2001-12-01 00:00:00

abstract：:A new era involving the evaluation of recombinant vaccines for colon cancer has begun with the concurrent emergence of insights and technologies in the fields of molecular biology and immunology. These advances include (I) the identification and cloning of an array of genes associated with the neoplastic process, such...

journal_title：Seminars in oncology

authors： Schlom J,Tsang KY,Kantor JA,Abrams SI,Zaremba S,Greiner J,Hodge JW

更新日期：1999-12-01 00:00:00

abstract：:Quality of life (QOL) is an important consideration in the treatment of patients with advanced lung cancer because treatment is largely palliative. Moreover, QOL predicts survival in non-small cell lung cancer, and there is increasing acceptance by clinicians and regulatory authorities of symptoms and QOL as primary o...

journal_title：Seminars in oncology

authors： Cella D

更新日期：2004-12-01 00:00:00

abstract：:Cisplatin is recognized as an active chemotherapeutic agent in a broad variety of human tumors. The severe emetic effects of cisplatin, however, result in both acute and delayed emesis syndromes causing considerable morbidity. Over the last decade, the standard of therapy for control of cisplatin-induced emesis has be...

journal_title：Seminars in oncology

authors： Perez EA,Hesketh PJ,Gandara DR

更新日期：1991-02-01 00:00:00

abstract：:Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) given as a 1-hour infusion potentially offers its recipients reduced toxicity, demonstrated efficacy, and greater ease of administration. To confirm this hypothesis, we undertook a phase I/II study of 1-hour, single-agent paclitaxel in 164 patients' refra...

journal_title：Seminars in oncology

authors： Hainsworth JD,Greco FA

更新日期：1995-12-01 00:00:00

abstract：:Targeted therapy for breast cancer has existed since 1986, when Beatson published his observations on oophorectomy. In the past 5 years monoclonal antibodies and tyrosine kinase inhibitors have been evaluated in phase I and II clinical trials of breast cancer. Trastuzumab (Herceptin; Genentech, Inc, South San Francisc...

journal_title：Seminars in oncology

authors： Kaklamani V,O'Regan RM

更新日期：2004-04-01 00:00:00

abstract：:Glioblastoma multiforme (GBM) is the most common form of primary malignant brain cancer. Median overall survival (OS) for newly diagnosed patients is only about 12 to 18 months. GBM tumors invariably recur, and there is no widely recognized and effective standard treatment for recurrent GBM. NovoTTF Therapy is a novel...

journal_title：Seminars in oncology

authors： Vymazal J,Wong ET

更新日期：2014-10-01 00:00:00

abstract：:Intra-arterial (IA) therapies for hepatocellular carcinoma (HCC) are considered palliative and should be offered to patients with intermediate-stage multinodular disease and with sufficient liver reserve. They include transarterial chemoembolization (TACE) or bland embolization, transarterial chemotherapy, and transar...

journal_title：Seminars in oncology

authors： Tsochatzis EA,Germani G,Burroughs AK

更新日期：2010-04-01 00:00:00

abstract：:An overview of the causes, the clinical pictures and the management of obstruction in three major organ systems due to primary and secondary malignant neoplasms has been presented. Such obstruction often produces dramatic clinical pictures that require careful, appropriate, and often aggressive therapy if patients are...

journal_title：Seminars in oncology

authors： Sise JG,Crichlow RW

更新日期：1978-06-01 00:00:00

abstract：:Docetaxel (Taxotere, Rhône-Poulenc Rorer, Antony, France) is highly effective in the first-line treatment of metastatic breast cancer, achieving an objective response rate of 61% (95% confidence interval, 52% to 69%). This rate of response is seen in patients with poor prognostic factors such as liver metastases and m...

journal_title：Seminars in oncology

authors： Trudeau ME

更新日期：1999-06-01 00:00:00

abstract：:Based on anecdotal cases of clinically important decreases in tumor size following initial evidence of disease progression when treating patients with anti-PD-1 therapies, investigators have conducted clinical trials in patients with metastatic non-small lung cancer (mNSCLC) receiving anti-PD-1 therapy allowing for tr...

journal_title：Seminars in oncology

authors： Kazandjian D,Keegan P,Suzman DL,Pazdur R,Blumenthal GM

更新日期：2017-02-01 00:00:00

abstract：:Because patients with metastatic bone disease suffer a significant burden from their illness and from anticancer treatments, it is therefore important to minimize the side effects of bisphosphonates. The intravenous bisphosphonates, zoledronic acid and pamidronate, have tolerability issues that include a flu-like synd...

journal_title：Seminars in oncology

authors： Body JJ,Diel I,Bell R

更新日期：2004-10-01 00:00:00